Perampanel May Reduce Seizures In Aggressive Brain Tumors

What was studied

This study looked at perampanel, a seizure medicine, used in patients with brain tumor-related epilepsy, particularly those with high-grade gliomas, which are aggressive brain tumors such as glioblastoma. The researchers were interested in whether perampanel could help control seizures, how well patients tolerated it, whether quality of life changed, and whether there was any link with survival.

It was a prospective, multicenter, real-world observational study from four neuro-oncology centers in Italy. Fourteen patients with brain tumor-related epilepsy took part and were followed for 6 months after starting perampanel.

What they found

Seizure frequency decreased during the 6-month follow-up, from 12.5 seizures per month to 3 seizures per month. About 78.6% of patients had their seizures reduced by at least half, and 57.1% were seizure-free. Side effects were described as mild overall, although 2 patients stopped taking perampanel. Quality-of-life analyses suggested possible improvement in communication and appetite, but these changes were not statistically significant. Survival analyses did not show significant associations with the clinical factors studied.

Limits of the evidence

This was a very small study with only 14 patients, so the results are uncertain. It was observational and did not include a comparison group, so it cannot show that perampanel was responsible for the seizure improvement. The follow-up lasted only 6 months, which limits what can be said about longer-term seizure control, side effects, quality of life, or survival. The abstract also says the findings are exploratory, and larger studies are needed to confirm efficacy, quality-of-life effects, and the influence of molecular factors.

For families and caregivers

For families, this study suggests that perampanel may help reduce seizures in some people with epilepsy related to brain tumors, including aggressive tumors, and it was generally well tolerated in this small group. It also suggests the medicine did not appear to worsen quality of life over the short term. Still, because the study was small and not a randomized trial, the results should be seen as early evidence rather than proof.

What to watch next

Stronger evidence would come from larger studies with comparison groups and longer follow-up to confirm seizure effects, quality-of-life findings, survival results, and side effects. Families can ask a clinician how perampanel fits with the patient’s other tumor and seizure treatments.

Terms in this summary

high-grade glioma

A fast-growing, aggressive brain tumor.

brain tumor-related epilepsy

Seizures that happen because of a brain tumor.

quality of life

How a person feels and functions in daily life, including symptoms and well-being.

responder rate

The percentage of patients whose seizures were reduced by at least half.

seizure-free

Having no seizures during the measured follow-up period.

observational study

A study where researchers watch what happens in regular care without randomly assigning treatments.

AMPA receptor

A protein on nerve cells involved in brain signaling that may play a role in seizures.